{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97"}]}],"title":"PFS rate at 12 months (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93"}]}],"title":"PFS rate at 24 months(%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80"}]}],"title":"PFS rate at 36 months(%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"76"}]}],"title":"PFS rate at 48 months(%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"72"}]}],"title":"PFS rate at 60 months(%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"description":"Progression-free Survival rate was estimated at months 12, 24, 36, 48, and 60, by the product-limit method of Kaplan and Meier.","groups":[{"description":"INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity..\n\nTRANSPLANT: Patients undergo autologous stem cell transplant.\n\nCONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity.\n\ndexamethasone: Given IV or PO\n\ncarfilzomib: Given IV\n\nlenalidomide: Given PO\n\nautologous hematopoietic stem cell transplantation: Undergo autologous hematopoietic stem cell transplant\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Dexamethasone, Carfilzomib, Lenalidomide)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percentage of Participants With Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}